Skip to main content

Immuneering Corp

IMRX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001790340

No open-market purchases or sales by Immuneering Corp insiders were filed in the last 90 days; 111 institutions reported holding it in 13F filings for Q2 2026, worth $171.6M in total; no superinvestor holds it.

Holders of 5% or more of IMRX

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Immuneering Corp, largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of IMRX
HolderLatest formStakeChangeFirst filedLatest filingFiling
Zeskind Benjamin J.13G/A12.80%3.98M shares–Jan 17, 20251 filingJan 17, 2025SEC
Empery Asset Management, LP13G8.83%5.19M sharesNewOct 21, 20251 filingOct 21, 2025SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

2 Schedule 13D and 13G filings on Immuneering Corp, newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on IMRX
Filed (ET)FilerFormStakeChangeEvent dateFiling
Oct 21, 20259:02 AM ETEmpery Asset Management, LPand 2 others13G8.83%5.19M sharesNewSep 30, 2025SEC
Jan 17, 20254:13 PM ETZeskind Benjamin J.13G/A12.80%3.98M shares–Dec 31, 2024SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Immuneering Corp shares.

No Form 144 notices for Immuneering Corp are on file.